Our team is studying elements of clinical trial design and reporting including crossover, the use of surrogate endpoints, and quality of life reporting. We also study HTA criteria for cancer drug reimbursement across several countries. Our work is synergistic with the Common Sense Oncology movement, of which Dr. Gyawali is a co-founder.
Explore some of our current work:
Dr. Bishal Gyawali 